Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HAE Haemonetics	$54.63 +0.5%	$67.99	$50.68 ▼ $94.99	$2.63B	0.4	1.32 million shs	826,354 shs
ICUI ICU Medical	$127.66 +0.5%	$126.87	$107.00 ▼ $196.26	$3.15B	0.88	393,938 shs	229,495 shs
MMSI Merit Medical Systems	$90.54 +0.5%	$88.41	$81.04 ▼ $111.45	$5.36B	0.66	478,851 shs	366,258 shs
STAA STAAR Surgical	$27.36 -0.1%	$21.43	$13.50 ▼ $38.60	$1.36B	0.61	3.41 million shs	506,411 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HAE Haemonetics	+0.35%	-2.93%	-28.12%	-19.28%	-27.24%
ICUI ICU Medical	+0.49%	-0.41%	+1.75%	-4.82%	-21.73%
MMSI Merit Medical Systems	+0.54%	+1.22%	+9.14%	-4.74%	-5.50%
STAA STAAR Surgical	-0.15%	-1.76%	+51.16%	+53.19%	-14.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HAE Haemonetics	4.9095 of 5 stars	4.4	3.0	4.3	1.9	1.7	3.1
ICUI ICU Medical	4.8413 of 5 stars	3.5	1.0	3.9	4.3	3.3	3.1
MMSI Merit Medical Systems	4.7133 of 5 stars	3.4	3.0	3.8	3.0	2.5	2.5
STAA STAAR Surgical	2.2082 of 5 stars	1.0	1.0	4.1	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HAE Haemonetics	2.83	Moderate Buy	$85.18	55.93% Upside
ICUI ICU Medical	3.00	Buy	$179.00	40.22% Upside
MMSI Merit Medical Systems	2.89	Moderate Buy	$107.00	18.18% Upside
STAA STAAR Surgical	2.00	Hold	$20.67	-24.46% Downside

Current Analyst Ratings Breakdown

Latest STAA, MMSI, ICUI, and HAE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	ICUI ICU Medical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$145.00
8/15/2025	ICUI ICU Medical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$145.00
8/11/2025	HAE Haemonetics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$105.00 ➝ $78.00
8/8/2025	HAE Haemonetics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$85.00 ➝ $62.00
8/8/2025	HAE Haemonetics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$90.00 ➝ $70.00
8/8/2025	HAE Haemonetics	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$95.00 ➝ $86.00
8/8/2025	ICUI ICU Medical	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$187.00 ➝ $180.00
8/7/2025	STAA STAAR Surgical	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Hold	$20.00 ➝ $28.00
8/7/2025	HAE Haemonetics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $68.00
8/6/2025	STAA STAAR Surgical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$20.00 ➝ $28.00
7/31/2025	MMSI Merit Medical Systems	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$108.00 ➝ $100.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HAE Haemonetics	$1.36B	1.93	$7.22 per share	7.57	$18.31 per share	2.98
ICUI ICU Medical	$2.38B	1.32	$14.03 per share	9.10	$85.71 per share	1.49
MMSI Merit Medical Systems	$1.36B	3.95	$5.61 per share	16.15	$25.13 per share	3.60
STAA STAAR Surgical	$313.90M	4.32	N/A	N/A	$6.79 per share	4.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HAE Haemonetics	$167.68M	$3.27	16.71	10.84	1.01	12.14%	26.64%	9.32%	11/6/2025 (Estimated)
ICUI ICU Medical	-$117.69M	-$1.52	N/A	23.47	N/A	-1.56%	7.24%	3.50%	11/11/2025 (Estimated)
MMSI Merit Medical Systems	$120.36M	$1.97	45.96	24.14	2.93	8.31%	15.07%	8.60%	10/29/2025 (Estimated)
STAA STAAR Surgical	-$20.21M	-$1.93	N/A	N/A	N/A	-42.45%	-16.11%	-12.54%	10/29/2025 (Estimated)

Latest STAA, MMSI, ICUI, and HAE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q1 2026	HAE Haemonetics	$1.01	$1.10	+$0.09	$0.70	$305.12 million	$321.39 million
8/7/2025	Q2 2025	ICUI ICU Medical	$1.44	$2.10	+$0.66	$1.43	$543.33 million	$543.57 million
7/30/2025	Q2 2025	MMSI Merit Medical Systems	$0.85	$1.01	+$0.16	$0.54	$372.47 million	$382.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HAE Haemonetics	N/A	N/A	N/A	N/A	N/A
ICUI ICU Medical	N/A	N/A	N/A	N/A	N/A
MMSI Merit Medical Systems	N/A	N/A	N/A	N/A	N/A
STAA STAAR Surgical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HAE Haemonetics	1.04	1.72	1.04
ICUI ICU Medical	0.63	2.44	1.17
MMSI Merit Medical Systems	0.49	4.09	2.66
STAA STAAR Surgical	N/A	4.94	4.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HAE Haemonetics	99.67%
ICUI ICU Medical	96.10%
MMSI Merit Medical Systems	99.66%
STAA STAAR Surgical	96.70%

Insider Ownership

Company	Insider Ownership
HAE Haemonetics	1.84%
ICUI ICU Medical	1.50%
MMSI Merit Medical Systems	3.20%
STAA STAAR Surgical	0.59%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HAE Haemonetics	3,023	48.18 million	47.29 million	Optionable
ICUI ICU Medical	15,000	24.69 million	24.32 million	Optionable
MMSI Merit Medical Systems	7,400	59.22 million	57.32 million	Optionable
STAA STAAR Surgical	1,211	49.55 million	49.26 million	Optionable

STAA, MMSI, ICUI, and HAE Headlines

Recent News About These Companies

Jump Financial LLC Acquires New Position in STAAR Surgical Company $STAA

August 30 at 5:00 AM | marketbeat.com

Charles Schwab Investment Management Inc. Has $7.39 Million Holdings in STAAR Surgical Company $STAA

August 29 at 3:14 AM | marketbeat.com

10,735 Shares in STAAR Surgical Company $STAA Acquired by EntryPoint Capital LLC

August 27 at 4:48 AM | marketbeat.com

Algert Global LLC Has $641,000 Stock Position in STAAR Surgical Company $STAA

August 26, 2025 | marketbeat.com

STAAR Surgical Company $STAA Shares Sold by Vanguard Group Inc.

August 25, 2025 | marketbeat.com

Quantbot Technologies LP Has $1.64 Million Stock Holdings in STAAR Surgical Company $STAA

August 24, 2025 | marketbeat.com

Alcon Inc. (NYSE:ALC) Q2 2025 Earnings Call Transcript

August 23, 2025 | msn.com

Public Sector Pension Investment Board Acquires 33,037 Shares of STAAR Surgical Company $STAA

August 22, 2025 | marketbeat.com

Brokerages Set STAAR Surgical Company (NASDAQ:STAA) Target Price at $20.67

August 22, 2025 | americanbankingnews.com

Iantrek raises $42m to fuel US glaucoma treatment launch

August 21, 2025 | medicaldevice-network.comM

STAAR Surgical Company (NASDAQ:STAA) Given Average Recommendation of "Hold" by Brokerages

August 20, 2025 | marketbeat.com

Lake Forest-based Staar Surgical to be Acquired in $1.5-Billion Transaction

August 19, 2025 | latimes.com

Connor Clark & Lunn Investment Management Ltd. Purchases 26,364 Shares of STAAR Surgical Company (NASDAQ:STAA)

August 18, 2025 | marketbeat.com

Resona Asset Management Co. Ltd. Raises Stake in STAAR Surgical Company (NASDAQ:STAA)

August 13, 2025 | marketbeat.com

Takeover Agreement with Alcon Sparks Sharp Weekly Gains for STAAR Surgical

August 13, 2025 | msn.com

Alcon to Acquire STAAR Surgical in $1.5 Billion Deal

August 12, 2025 | theglobeandmail.com

Staar Surgical (STAA) International Revenue in Focus: Trends and Expectations

August 11, 2025 | zacks.com

Staar Surgical’s Merger Faces Hurdles: Stockholder Approval and Regulatory Challenges Loom

August 10, 2025 | theglobeandmail.com

STAAR Surgical (STAA) Q2 Revenue Tops 9%

August 10, 2025 | theglobeandmail.com

Stifel Downgrades STAAR Surgical (STAA)

August 8, 2025 | msn.com

STAAR Surgical's largest holder demands books, records on Alcon deal

August 8, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STAA, MMSI, ICUI, and HAE Company Descriptions

Haemonetics NYSE:HAE

$54.63 +0.29 (+0.53%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$56.25 +1.62 (+2.97%)

As of 08/29/2025 07:55 PM Eastern

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

ICU Medical NASDAQ:ICUI

$127.66 +0.62 (+0.49%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$127.66 0.00 (0.00%)

As of 08/29/2025 04:20 PM Eastern

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

Merit Medical Systems NASDAQ:MMSI

$90.54 +0.49 (+0.54%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$89.20 -1.34 (-1.48%)

As of 08/29/2025 04:20 PM Eastern

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.

STAAR Surgical NASDAQ:STAA

$27.36 -0.04 (-0.15%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$27.28 -0.07 (-0.27%)

As of 08/29/2025 04:20 PM Eastern

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time